Jaguar Health, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
JAGX$0.44+7.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended · Nine Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|
| September 30, · September 30, | ||||||||
| (In thousands, except share and per share data) · 2025 · 2024 · 2025 · 2024 | ||||||||
| Product revenue, net | $ | 3,041 | $ | 3,066 | $ | 8,148 | $ | 8,095 |
| License revenue | 42 | 42 | 128 | 85 | ||||
| Total revenue, net | 3,083 | 3,108 | 8,276 | 8,180 | ||||
| Operating expenses | ||||||||
| Cost of product revenue | 532 | 541 | 1,574 | 1,398 | ||||
| Research and development | 3,658 | 4,043 | 10,653 | 12,008 | ||||
| Sales and marketing | 1,997 | 2,010 | 6,957 | 4,977 | ||||
| General and administrative | 4,134 | 3,776 | 13,758 | 12,471 | ||||
| Total operating expenses | 10,321 | 10,370 | 32,942 | 30,854 | ||||
| Loss from operations | (7,238) | (7,262) | (24,666) | (22,674) | ||||
| Gain (loss) on extinguishment of debt | — | — | (1,822) | 1,245 | ||||
| Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option | (2,310) | (3,089) | (4,721) | (6,920) | ||||
| Interest income (expense) | (6) | 162 | 65 | (341) | ||||
| Other income (expense) | (94) | 168 | 340 | (327) | ||||
| Loss before income tax expense | (9,648) | (10,021) | (30,804) | (29,017) | ||||
| Income tax expense | — | — | — | — | ||||
| Net loss | $ | (9,648) | $ | (10,021) | $ | (30,804) | $ | (29,017) |
| Net loss attributable to noncontrolling interest | $ | (146) | $ | (167) | $ | (431) | $ | (445) |
| Net loss attributable to common stockholders | $ | (9,502) | $ | (9,854) | $ | (30,373) | $ | (28,572) |
| Net loss per share, basic and diluted | $ | (6.28) | $ | (26.29) | $ | (22.61) | $ | (150.72) |
| Weighted-average common stock outstanding, basic and diluted | 1,513,178 | 374,805 | 1,343,443 | 189,567 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.